{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:59:00Z","timestamp":1790369940799,"version":"4.1.0"},"reference-count":166,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs) have significantly expanded the therapeutic landscape of multiple myeloma (MM), contributing to deeper and more durable responses and meaningful survival benefits across the continuum of the disease. CD38-targeting mAbs are now integral to frontline regimens, while ADCs introduce a complementary strategy by enabling targeted delivery of cytotoxic payloads, most notably through B-cell maturation antigen (BCMA). However, the clinical integration of these agents has revealed new resistant mechanisms, including antigen loss, immune exhaustion, and the emergence of cross-resistance across BCMA-directed therapies. Furthermore, challenges in the sequencing of treatments have emerged, as novel immunotherapies have also become available in the early relapse setting. This contemporary review examines the evolving role of mAbs and ADCs in MM, addressing both current status and directions for future research in the field.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000845","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:01:14Z","timestamp":1790366474000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Monoclonal Antibodies and Antibody-Drug Conjugates"],"prefix":"10.1097","volume":"32","author":[{"given":"Ioannis","family":"Ntanasis-Stathopoulos","sequence":"first","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios-Athanasios","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"},{"name":"Department of Medicine, Korea University, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9]]},"reference":[{"key":"R1-20260925","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"R2-20260925","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1158\/2643-3230.BCD-25-0384","article-title":"First-line therapy in newly diagnosed multiple myeloma","volume":"7","author":"Miller","year":"2026","journal-title":"Blood Cancer Discov"},{"key":"R3-20260925","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1002\/ajh.70012","article-title":"Determinants of 15-year progression-free survival in multiple myeloma; real-world data from a single institution","volume":"100","author":"Dimopoulos","year":"2025","journal-title":"Am J Hematol"},{"key":"R4-20260925","first-page":"1","article-title":"A review of the clinical efficacy of monoclonal antibody (mAb)-based therapies for relapsed\/refractory multiple myeloma (RRMM)","author":"Liu","year":"2026","journal-title":"Expert Opin Biol Ther"},{"key":"R5-20260925","doi-asserted-by":"crossref","first-page":"1687718","DOI":"10.3389\/fphar.2025.1687718","article-title":"Cluster of differentiation 38 monoclonal antibody therapy in the treatment of multiple myeloma: a systematic review and meta-analysis","volume":"16","author":"Guo","year":"2025","journal-title":"Front Pharmacol"},{"key":"R6-20260925","doi-asserted-by":"crossref","first-page":"1613265","DOI":"10.3389\/fimmu.2025.1613265","article-title":"Deciphering the bone marrow microenvironment\u2019s role in multiple myeloma immunotherapy resistance","volume":"16","author":"Iannozzi","year":"2025","journal-title":"Front Immunol"},{"key":"R7-20260925","doi-asserted-by":"crossref","first-page":"e699","DOI":"10.1016\/j.clml.2026.03.003","article-title":"The evolution of chimeric antigen receptor T-cell, bispecific antibodies and antibody-drug conjugates for the treatment of multiple myeloma","volume":"26","author":"Cani","year":"2026","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R8-20260925","doi-asserted-by":"crossref","first-page":"4088","DOI":"10.3390\/jcm10184088","article-title":"BCMA in multiple myeloma\u2014a promising key to therapy","volume":"10","author":"Kleber","year":"2021","journal-title":"J Clin Med"},{"key":"R9-20260925","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrc3930","article-title":"Building better monoclonal antibody-based therapeutics","volume":"15","author":"Weiner","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"R10-20260925","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/imr.12389","article-title":"Monoclonal antibodies targeting CD38 in hematological malignancies and beyond","volume":"270","author":"van de Donk","year":"2016","journal-title":"Immunol Rev"},{"key":"R11-20260925","doi-asserted-by":"crossref","first-page":"100151","DOI":"10.1016\/j.bneo.2025.100151","article-title":"Neutrophil-mediated trogocytosis as a new mechanism of action of daratumumab","volume":"2","author":"Lorenzo-Mohamed","year":"2025","journal-title":"Blood Neoplasia"},{"key":"R12-20260925","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"Mabs"},{"key":"R13-20260925","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J Immunol"},{"key":"R14-20260925","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1158\/1078-0432.CCR-18-1597","article-title":"The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma","volume":"25","author":"Moreno","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R15-20260925","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"R16-20260925","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: back to the future","volume":"131","author":"van de Donk","year":"2018","journal-title":"Blood"},{"key":"R17-20260925","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.3390\/cancers14112768","article-title":"Daratumumab improves bone turnover in relapsed\/refractory multiple myeloma; phase 2 study \u201cREBUILD","volume":"14","author":"Terpos","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R18-20260925","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/ajh.27206","article-title":"Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy: final results of the phase 2 study DARIA","volume":"99","author":"Terpos","year":"2024","journal-title":"Am J Hematol"},{"key":"R19-20260925","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1186\/s12885-025-15250-1","article-title":"The effects of daratumumab on bone disease in patients with newly diagnosed multiple myeloma: a multi-center retrospective study","volume":"25","author":"Li","year":"2025","journal-title":"BMC Cancer"},{"key":"R20-20260925","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s00262-013-1493-8","article-title":"Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC","volume":"62","author":"Collins","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"R21-20260925","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R22-20260925","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","article-title":"EHA-EMN evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma","volume":"22","author":"Dimopoulos","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"R23-20260925","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1056\/NEJMoa2409029","article-title":"Daratumumab or active monitoring for high-risk smoldering multiple myeloma","volume":"392","author":"Dimopoulos","year":"2025","journal-title":"N Engl J Med"},{"key":"R24-20260925","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/s41375-024-02505-2","article-title":"Daratumumab\/lenalidomide\/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes","volume":"39","author":"Facon","year":"2025","journal-title":"Leukemia"},{"key":"R25-20260925","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol"},{"key":"R26-20260925","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"key":"R27-20260925","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet"},{"key":"R28-20260925","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"key":"R29-20260925","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S1470-2045(25)00018-X","article-title":"Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial","volume":"26","author":"Mateos","year":"2025","journal-title":"Lancet Oncol"},{"key":"R30-20260925","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","volume":"31","author":"Usmani","year":"2025","journal-title":"Nat Med"},{"key":"R31-20260925","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"R32-20260925","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S1470-2045(21)00428-9","article-title":"Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"key":"R33-20260925","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S1470-2045(24)00282-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial","volume":"25","author":"Moreau","year":"2024","journal-title":"Lancet Oncol"},{"key":"R34-20260925","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood.2024027620","article-title":"Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results","volume":"146","author":"Corre","year":"2025","journal-title":"Blood"},{"key":"R35-20260925","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","article-title":"Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial","volume":"10","author":"Voorhees","year":"2023","journal-title":"Lancet Haematol"},{"key":"R36-20260925","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/bloodadvances.2020003642","article-title":"Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN","volume":"5","author":"Voorhees","year":"2021","journal-title":"Blood Adv"},{"key":"R37-20260925","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"R38-20260925","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1182\/blood.2025030113","article-title":"Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone","volume":"147","author":"Bertamini","year":"2026","journal-title":"Blood"},{"key":"R39-20260925","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"key":"R40-20260925","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J Clin Oncol"},{"key":"R41-20260925","doi-asserted-by":"crossref","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","article-title":"Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial","volume":"10","author":"Costa","year":"2023","journal-title":"Lancet Haematol"},{"key":"R42-20260925","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"R43-20260925","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1200\/JCO.22.00940","article-title":"Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): a randomized, open-label, phase III trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J Clin Oncol"},{"key":"R44-20260925","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1038\/s41375-020-0711-6","article-title":"Daratumumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study","volume":"34","author":"Bahlis","year":"2020","journal-title":"Leukemia"},{"key":"R45-20260925","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.3324\/haematol.2018.194282","article-title":"Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX","volume":"103","author":"Dimopoulos","year":"2018","journal-title":"Haematologica"},{"key":"R46-20260925","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"key":"R47-20260925","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"key":"R48-20260925","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.3324\/haematol.2018.194118","article-title":"Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR","volume":"103","author":"Spencer","year":"2018","journal-title":"Haematologica"},{"key":"R49-20260925","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.clml.2019.09.623","article-title":"Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: three-year follow-up of CASTOR","volume":"20","author":"Mateos","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R50-20260925","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1200\/JCO.21.02734","article-title":"Overall survival with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma (CASTOR): a randomized, open-label, phase III trial","volume":"41","author":"Sonneveld","year":"2023","journal-title":"J Clin Oncol"},{"key":"R51-20260925","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol"},{"key":"R52-20260925","doi-asserted-by":"crossref","first-page":"e813","DOI":"10.1016\/S2352-3026(23)00218-1","article-title":"Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial","volume":"10","author":"Dimopoulos","year":"2023","journal-title":"Lancet Haematol"},{"key":"R53-20260925","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"key":"R54-20260925","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(21)00579-9","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study","volume":"23","author":"Usmani","year":"2022","journal-title":"Lancet Oncol"},{"key":"R55-20260925","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/bloodadvances.2023010026","article-title":"Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study","volume":"7","author":"Usmani","year":"2023","journal-title":"Blood Adv"},{"key":"R56-20260925","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.3324\/haematol.2021.279459","article-title":"Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma","volume":"107","author":"Usmani","year":"2022","journal-title":"Haematologica"},{"key":"R57-20260925","doi-asserted-by":"crossref","first-page":"e370","DOI":"10.1016\/S2352-3026(20)30070-3","article-title":"Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial","volume":"7","author":"Mateos","year":"2020","journal-title":"Lancet Haematol"},{"key":"R58-20260925","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S2352-3026(20)30081-8","article-title":"Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials","volume":"7","author":"Usmani","year":"2020","journal-title":"Lancet Haematol"},{"key":"R59-20260925","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1200\/JCO.20.01814","article-title":"Evaluation of sustained minimal residual disease negativity with daratumumab-combination regimens in relapsed and\/or refractory multiple myeloma: analysis of POLLUX and CASTOR","volume":"39","author":"Avet-Loiseau","year":"2021","journal-title":"J Clin Oncol"},{"key":"R60-20260925","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/blood.2021011101","article-title":"Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA","volume":"139","author":"Cavo","year":"2022","journal-title":"Blood"},{"key":"R61-20260925","doi-asserted-by":"crossref","first-page":"115157","DOI":"10.1016\/j.ejca.2024.115157","article-title":"Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: analysis of individual patient-level data from daratumumab clinical trials","volume":"215","author":"Yong","year":"2025","journal-title":"Eur J Cancer"},{"key":"R62-20260925","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.2020010439","article-title":"Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE","volume":"139","author":"San-Miguel","year":"2022","journal-title":"Blood"},{"key":"R63-20260925","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ajh.27582","article-title":"Evaluating minimal residual disease negativity as a surrogate endpoint for treatment efficacy in multiple myeloma: a meta-analysis of randomized controlled trials","volume":"100","author":"Ntanasis-Stathopoulos","year":"2025","journal-title":"Am J Hematol"},{"key":"R64-20260925","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"key":"R65-20260925","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1182\/blood.2025030120","article-title":"Isatuximab, bortezomib, lenalidomide, dexamethasone for multiple myeloma: dynamics of MRD-negativity in the IMROZ study","volume":"147","author":"Orlowski","year":"2026","journal-title":"Blood"},{"key":"R66-20260925","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","article-title":"Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial","volume":"9","author":"Goldschmidt","year":"2022","journal-title":"Lancet Haematol"},{"key":"R67-20260925","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1200\/JCO-24-02266","article-title":"Isatuximab, lenalidomide, bortezomib, and dexamethasone induction therapy for transplant-eligible newly diagnosed multiple myeloma: final part 1 analysis of the GMMG-HD7 trial","volume":"43","author":"Mai","year":"2025","journal-title":"J Clin Oncol"},{"key":"R68-20260925","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/s41591-024-03050-2","article-title":"Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial","volume":"30","author":"Leleu","year":"2024","journal-title":"Nat Med"},{"key":"R69-20260925","first-page":"2760","article-title":"Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial","volume":"147","author":"Gay","year":"2026","journal-title":"Nat Med"},{"key":"R70-20260925","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.3324\/haematol.2023.284325","article-title":"Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis","volume":"109","author":"Richardson","year":"2024","journal-title":"Haematologica"},{"key":"R71-20260925","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(22)00019-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study","volume":"23","author":"Richardson","year":"2022","journal-title":"Lancet Oncol"},{"key":"R72-20260925","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"key":"R73-20260925","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"key":"R74-20260925","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41408-023-00797-8","article-title":"Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study","volume":"13","author":"Martin","year":"2023","journal-title":"Blood Cancer J"},{"key":"R75-20260925","doi-asserted-by":"crossref","first-page":"e741","DOI":"10.1016\/S2352-3026(24)00148-0","article-title":"Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial","volume":"11","author":"Yong","year":"2024","journal-title":"Lancet Haematol"},{"key":"R76-20260925","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO-25-00744","article-title":"Isatuximab subcutaneous by on-body injector versus isatuximab intravenous plus pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma: phase III IRAKLIA study","volume":"43","author":"Ailawadhi","year":"2025","journal-title":"J Clin Oncol"},{"key":"R77-20260925","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41408-025-01436-0","article-title":"Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed\/refractory multiple myeloma: results of the phase 2 study IZALCO","volume":"16","author":"Parmar","year":"2025","journal-title":"Blood Cancer J"},{"issue":"7-8","key":"R78-20260925","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1080\/13543784.2025.2532446","article-title":"Isatuximab for the treatment of multiple myeloma: current clinical advances and future directions","volume":"34","author":"Richardson","year":"2025","journal-title":"Expert Opin Investig Drugs"},{"key":"R79-20260925","doi-asserted-by":"crossref","first-page":"116222","DOI":"10.1016\/j.intimp.2026.116222","article-title":"Cyclophosphamide-pomalidomide combination alters the tumour cell secretome and enhances the anti-myeloma activity of elotuzumab through NK cell-mediated cytotoxicity","volume":"175","author":"Feerick","year":"2026","journal-title":"Int Immunopharmacol"},{"key":"R80-20260925","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"key":"R81-20260925","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41408-020-00357-4","article-title":"Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study","volume":"10","author":"Dimopoulos","year":"2020","journal-title":"Blood Cancer J"},{"key":"R82-20260925","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1200\/JCO.21.02815","article-title":"Elotuzumab plus pomalidomide and dexamethasone for relapsed\/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT-3 trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J Clin Oncol"},{"key":"R83-20260925","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med"},{"key":"R84-20260925","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/S2352-3026(20)30354-9","article-title":"Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial","volume":"8","author":"Usmani","year":"2021","journal-title":"Lancet Haematol"},{"key":"R85-20260925","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1177\/10781552221103551","article-title":"Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma","volume":"29","author":"Mateos","year":"2023","journal-title":"J Oncol Pharm Pract"},{"key":"R86-20260925","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.clml.2021.02.014","article-title":"Transition from intravenous to subcutaneous daratumumab formulation in clinical practice","volume":"21","author":"Hamadeh","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R87-20260925","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00432-020-03365-w","article-title":"Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results","volume":"147","author":"Usmani","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"R88-20260925","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/bjh.16980","article-title":"Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label phase II study","volume":"192","author":"Chari","year":"2021","journal-title":"Br J Haematol"},{"key":"R89-20260925","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/s41375-020-0876-z","article-title":"Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)","volume":"34","author":"Terpos","year":"2020","journal-title":"Leukemia"},{"key":"R90-20260925","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/s41375-023-01920-1","article-title":"Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)","volume":"37","author":"Terpos","year":"2023","journal-title":"Leukemia"},{"key":"R91-20260925","doi-asserted-by":"crossref","first-page":"21480","DOI":"10.1002\/cam4.6699","article-title":"Improved efficiency of daratumumab treatment of multiple myeloma adopting the subcutaneous route: a micro-costing analysis in three Italian hematology centers","volume":"12","author":"Pradelli","year":"2023","journal-title":"Cancer Med"},{"key":"R92-20260925","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41571-026-01119-0","article-title":"Diagnosis, risk stratification and management of smouldering multiple myeloma","volume":"23","author":"Zanwar","year":"2026","journal-title":"Nat Rev Clin Oncol"},{"key":"R93-20260925","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood.2024025897","article-title":"Efficacy and safety of daratumumab in intermediate\/high-risk smoldering multiple myeloma: final analysis of CENTAURUS","volume":"145","author":"Landgren","year":"2025","journal-title":"Blood"},{"key":"R94-20260925","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41375-020-0718-z","article-title":"Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)","volume":"34","author":"Landgren","year":"2020","journal-title":"Leukemia"},{"key":"R95-20260925","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMc2507790","article-title":"Daratumumab for high-risk smoldering multiple myeloma","volume":"393","author":"Shanmugam","year":"2025","journal-title":"N Engl J Med"},{"key":"R96-20260925","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13045-025-01711-4","article-title":"Practice-changing updates on multiple myeloma: highlights from the 2024 ASH annual meeting","volume":"18","author":"Ntanasis-Stathopoulos","year":"2025","journal-title":"J Hematol Oncol"},{"key":"R97-20260925","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s40265-016-0573-4","article-title":"Practical considerations for the use of daratumumab, a novel CD38 monoclonal antibody, in myeloma","volume":"76","author":"Moreau","year":"2016","journal-title":"Drugs"},{"key":"R98-20260925","doi-asserted-by":"crossref","first-page":"e70128","DOI":"10.1002\/cam4.70128","article-title":"Impact of M-protein detection on the response evaluations of patients undergoing treatment with the IgG-kappa monoclonal antibodies daratumumab or isatuximab, and discrepancies between immunofixation electrophoresis (IFE) systems and reagents","volume":"13","author":"Shirouchi","year":"2024","journal-title":"Cancer Med"},{"key":"R99-20260925","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3960\/jslrt.25058","article-title":"Evaluation of the performance of new daratumumab-specific immunofixation electrophoresis reflex agent and the timing of M-protein measurement","volume":"65","author":"Yasuda","year":"2025","journal-title":"J Clin Exp Hematop"},{"key":"R100-20260925","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1515\/cclm-2015-0888","article-title":"Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA)","volume":"54","author":"van de Donk","year":"2016","journal-title":"Clin Chem Lab Med"},{"key":"R101-20260925","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/imj.13707","article-title":"Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma","volume":"48","author":"Quach","year":"2018","journal-title":"Intern Med J"},{"key":"R102-20260925","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.clml.2017.09.002","article-title":"Blood transfusion management and transfusion-related outcomes in daratumumab-treated patients with relapsed or refractory multiple myeloma","volume":"18","author":"Chari","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R103-20260925","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.3389\/fimmu.2018.02616","article-title":"Blood transfusion management for patients treated with anti-CD38 monoclonal antibodies","volume":"9","author":"Lancman","year":"2018","journal-title":"Front Immunol"},{"key":"R104-20260925","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/1744666X.2018.1443809","article-title":"CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience","volume":"14","author":"Frerichs","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"R105-20260925","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1080\/10428194.2023.2172982","article-title":"Cytomegalovirus and Epstein-Barr virus infection during daratumumab treatment in patients with multiple myeloma","volume":"64","author":"Li","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"R106-20260925","doi-asserted-by":"crossref","first-page":"1729177","DOI":"10.3389\/fonc.2025.1729177","article-title":"Infection risks associated with daratumumab-containing regimens in multiple myeloma: a systematic review and meta-analysis","volume":"15","author":"Huang","year":"2025","journal-title":"Front Oncol"},{"key":"R107-20260925","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12185-024-03770-8","article-title":"Cytomegalovirus infection during daratumumab therapy in patients with newly diagnosed multiple myeloma","volume":"120","author":"Kikuchi","year":"2024","journal-title":"Int J Hematol"},{"key":"R108-20260925","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haematol"},{"key":"R109-20260925","doi-asserted-by":"crossref","first-page":"E226","DOI":"10.1002\/ajh.27001","article-title":"Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed\/refractory multiple myeloma and severe renal impairment or on dialysis: the DARE study","volume":"98","author":"Kastritis","year":"2023","journal-title":"Am J Hematol"},{"key":"R110-20260925","doi-asserted-by":"crossref","first-page":"2399430","DOI":"10.1080\/16078454.2024.2399430","article-title":"Efficacy of daratumumab on multiple myeloma patients with renal insufficiency: a systematic review and meta-analysis","volume":"29","author":"Jiang","year":"2024","journal-title":"Hematology"},{"key":"R111-20260925","first-page":"1397","article-title":"Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis","volume":"107","author":"Capra","journal-title":"Haematologica 2022"},{"key":"R112-20260925","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1182\/bloodadvances.2025015901","article-title":"Early daratumumab therapy improves renal outcomes in newly diagnosed patients with myeloma admitted with kidney injury","volume":"9","author":"Kim","year":"2025","journal-title":"Blood Adv"},{"key":"R113-20260925","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"R114-20260925","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11523-025-01189-7","article-title":"Antibody-drug conjugates, T-cell engager bispecific antibodies and chimeric antigen receptor T cells for multiple myeloma: what\u2019s the current status?","volume":"21","author":"Segers","year":"2026","journal-title":"Target Oncol"},{"key":"R115-20260925","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/14712598.2020.1802422","article-title":"Antibody-drug conjugates for multiple myeloma","volume":"21","author":"McMillan","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"R116-20260925","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41568-024-00690-x","article-title":"Cancer therapy with antibodies","volume":"24","author":"Paul","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"R117-20260925","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/s41568-025-00869-w","article-title":"Unveiling the molecular and immunological drivers of antibody-drug conjugates in cancer treatment","volume":"25","author":"Zippelius","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"R118-20260925","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front Immunol"},{"key":"R119-20260925","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"key":"R120-20260925","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1002\/cncr.33809","article-title":"Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study","volume":"127","author":"Lonial","year":"2021","journal-title":"Cancer"},{"key":"R121-20260925","doi-asserted-by":"crossref","first-page":"e801","DOI":"10.1016\/S2352-3026(23)00243-0","article-title":"Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study","volume":"10","author":"Dimopoulos","year":"2023","journal-title":"Lancet Haematol"},{"key":"R122-20260925","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S1470-2045(25)00330-4","article-title":"Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial","volume":"26","author":"Hungria","year":"2025","journal-title":"Lancet Oncol"},{"key":"R123-20260925","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa2405090","article-title":"Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma","volume":"391","author":"Hungria","year":"2024","journal-title":"N Engl J Med"},{"key":"R124-20260925","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2403407","article-title":"Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma","volume":"391","author":"Dimopoulos","year":"2024","journal-title":"N Engl J Med"},{"key":"R125-20260925","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1182\/blood.2025031629","article-title":"Belantamab mafodotin, lenalidomide, and dexamethasone for intermediate-fit and frail patients with newly diagnosed myeloma","volume":"147","author":"Terpos","year":"2026","journal-title":"Blood"},{"key":"R126-20260925","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.3390\/cancers15112948","article-title":"Belantamab mafodotin: from clinical trials data to real-life experiences","volume":"15","author":"More","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R127-20260925","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1002\/ajh.70015","article-title":"Practical guidance on clinical management of belantamab mafodotin-associated ocular events","volume":"100","author":"Terpos","year":"2025","journal-title":"Am J Hematol"},{"key":"R128-20260925","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","article-title":"Corneal epithelial findings in patients with multiple myeloma treated with antibody-drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study","volume":"9","author":"Farooq","year":"2020","journal-title":"Ophthalmol Ther"},{"key":"R129-20260925","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-025-01212-0","article-title":"The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development","volume":"15","author":"Mukhopadhyay","year":"2025","journal-title":"Blood Cancer J"},{"key":"R130-20260925","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41591-023-02703-y","article-title":"Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1\/2 trial","volume":"30","author":"Trudel","year":"2024","journal-title":"Nat Med"},{"key":"R131-20260925","doi-asserted-by":"crossref","first-page":"e876","DOI":"10.1016\/S2352-3026(25)00256-X","article-title":"Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial","volume":"12","author":"Dimopoulos","year":"2025","journal-title":"Lancet Haematol"},{"key":"R132-20260925","doi-asserted-by":"crossref","first-page":"e599","DOI":"10.1016\/S2352-3026(25)00163-2","article-title":"Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial","volume":"12","author":"Hungria","year":"2025","journal-title":"Lancet Haematol"},{"key":"R133-20260925","doi-asserted-by":"crossref","first-page":"5708","DOI":"10.1182\/bloodadvances.2025016949","article-title":"Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials","volume":"9","author":"Mateos","year":"2025","journal-title":"Blood Adv"},{"key":"R134-20260925","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.3324\/haematol.2023.284347","article-title":"Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: part 1 results of a phase I\/II study","volume":"109","author":"Terpos","year":"2024","journal-title":"Haematologica"},{"key":"R135-20260925","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/ajh.27219","article-title":"Belantamab mafodotin, lenalidomide, and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: analysis of belantamab mafodotin-associated ocular adverse events and their impact on daily functioning from the part 1 of a phase 1\/2 study","volume":"99","author":"Gavriatopoulou","year":"2024","journal-title":"Am J Hematol"},{"key":"R136-20260925","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1111\/bjh.70116","article-title":"Emerging role of G protein-coupled receptor class C group 5 member D-directed immunotherapy in multiple myeloma: advances, resistance and combination strategies","volume":"207","author":"Wang","year":"2025","journal-title":"Br J Haematol"},{"key":"R137-20260925","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1182\/bloodadvances.2023010856","article-title":"Beyond BCMA: newer immune targets in myeloma","volume":"8","author":"Tan","year":"2024","journal-title":"Blood Adv"},{"key":"R138-20260925","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"key":"R139-20260925","doi-asserted-by":"crossref","first-page":"7498","DOI":"10.1158\/1078-0432.CCR-17-2027","article-title":"Monocytes and granulocytes reduce CD38 expression levels on myeloma cells in patients treated with daratumumab","volume":"23","author":"Krejcik","year":"2017","journal-title":"Clin Cancer Res"},{"key":"R140-20260925","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1182\/blood.2024028107","article-title":"Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma","volume":"146","author":"Diamond","year":"2025","journal-title":"Blood"},{"key":"R141-20260925","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1182\/blood.2023023557","article-title":"Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma","volume":"144","author":"Firestone","year":"2024","journal-title":"Blood"},{"key":"R142-20260925","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.3390\/cancers13133213","article-title":"Mechanisms of immune evasion in multiple myeloma: open questions and therapeutic opportunities","volume":"13","author":"Botta","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R143-20260925","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3390\/jcm9041195","article-title":"Resistance mechanisms towards CD38-directed antibody therapy in multiple myeloma","volume":"9","author":"Franssen","year":"2020","journal-title":"J Clin Med"},{"key":"R144-20260925","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.3389\/fimmu.2018.02134","article-title":"CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance","volume":"9","author":"van de Donk","year":"2018","journal-title":"Front Immunol"},{"key":"R145-20260925","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1038\/ncomms8333","article-title":"Gamma-secretase directly sheds the survival receptor BCMA from plasma cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat Commun"},{"key":"R146-20260925","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3390\/cells14141077","article-title":"Resistance mechanisms to BCMA targeting bispecific antibodies and CAR T-cell therapies in multiple myeloma","volume":"14","author":"Tedder","year":"2025","journal-title":"Cells"},{"key":"R147-20260925","doi-asserted-by":"crossref","first-page":"101256","DOI":"10.1016\/j.blre.2025.101256","article-title":"Mechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma","volume":"70","author":"Yue","year":"2025","journal-title":"Blood Rev"},{"key":"R148-20260925","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.3390\/cancers17121943","article-title":"Upfront anti-CD38 monoclonal antibody-based quadruplet therapy for multiple myeloma: a systematic review and meta-analysis of clinical trials","volume":"17","author":"Ntanasis-Stathopoulos","year":"2025","journal-title":"Cancers (Basel)"},{"key":"R149-20260925","doi-asserted-by":"crossref","first-page":"e975","DOI":"10.1097\/HS9.0000000000000975","article-title":"Management and outcomes of anti-CD38 refractory patients: the impact of retreatment and of subsequent therapies","volume":"7","author":"Kastritis","year":"2023","journal-title":"Hemasphere"},{"key":"R150-20260925","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1038\/s41375-025-02677-5","article-title":"The impact of high-risk cytogenetics on treatment efficacy and outcomes of patients with relapsed\/refractory multiple myeloma: a systematic review and meta-analysis of randomized controlled trials","volume":"39","author":"Ntanasis-Stathopoulos","year":"2025","journal-title":"Leukemia"},{"key":"R151-20260925","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/ajh.27327","article-title":"High-risk multiple myeloma: redefining genetic, clinical, and functional high-risk disease in the era of molecular medicine and immunotherapy","volume":"99","author":"Rees","year":"2024","journal-title":"Am J Hematol"},{"key":"R152-20260925","doi-asserted-by":"crossref","first-page":"e433520","DOI":"10.1200\/EDBK_433520","article-title":"Navigating high-risk and ultrahigh-risk multiple myeloma: challenges and emerging strategies","volume":"44","author":"Rees","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R153-20260925","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.clml.2025.10.004","article-title":"SOHO state of the art updates and next questions | treatment of myeloma early relapse: non-CAR T cell","volume":"26","author":"Gavriatopoulou","year":"2026","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R154-20260925","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1002\/ajh.70070","article-title":"European Myeloma Network consensus statement on functional high-risk multiple myeloma","volume":"100","author":"Lim","year":"2025","journal-title":"Am J Hematol"},{"key":"R155-20260925","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/ajh.27661","article-title":"Belantamab mafodotin plus proteasome inhibition efficacy versus comparators in early relapsed myeloma: a systematic review and network meta-analysis","volume":"100","author":"Richter","year":"2025","journal-title":"Am J Hematol"},{"key":"R156-20260925","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14051655","article-title":"Current treatment strategies for multiple myeloma at first relapse","volume":"14","author":"Mavrothalassitis","year":"2025","journal-title":"J Clin Med"},{"key":"R157-20260925","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41375-024-02482-6","article-title":"International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma","volume":"39","author":"Costa","year":"2025","journal-title":"Leukemia"},{"key":"R158-20260925","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1007\/s12325-025-03205-8","article-title":"Comparative efficacy of ciltacabtagene autoleucel versus standard-of-care treatments for patients with previously treated relapsed or refractory multiple myeloma: a matching-adjusted indirect comparison","volume":"42","author":"Puig","year":"2025","journal-title":"Adv Ther"},{"key":"R159-20260925","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-023-00886-8","article-title":"Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy","volume":"13","author":"Ferreri","year":"2023","journal-title":"Blood Cancer J"},{"key":"R160-20260925","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"key":"R161-20260925","doi-asserted-by":"crossref","first-page":"e70260","DOI":"10.1002\/hem3.70260","article-title":"Sequencing BCMA- and GPRC5D-targeting immunotherapies in multiple myeloma: practical guidance from the European Myeloma Network","volume":"9","author":"van de Donk","year":"2025","journal-title":"Hemasphere"},{"key":"R162-20260925","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1056\/NEJMoa2514663","article-title":"Teclistamab plus daratumumab in relapsed or refractory multiple myeloma","volume":"394","author":"Costa","year":"2026","journal-title":"N Engl J Med"},{"key":"R163-20260925","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2603870","article-title":"Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy","author":"Touzeau","year":"2026","journal-title":"N Engl J Med"},{"key":"R164-20260925","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood.2023023616","article-title":"Efficacy and safety of teclistamab in patients with relapsed\/refractory multiple myeloma after BCMA-targeting therapies","volume":"144","author":"Touzeau","year":"2024","journal-title":"Blood"},{"key":"R165-20260925","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","article-title":"Real-world analysis of teclistamab in 123 RRMM patients from Germany","volume":"38","author":"Riedhammer","year":"2024","journal-title":"Leukemia"},{"key":"R166-20260925","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41408-024-01043-5","article-title":"Comparison of infectious complications with BCMA-directed therapies in multiple myeloma","volume":"14","author":"Nath","year":"2024","journal-title":"Blood Cancer J"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/PPO.0000000000000845","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:01:32Z","timestamp":1790366492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/PPO.0000000000000845"}},"subtitle":["Expanding the Therapeutic Arsenal in Multiple Myeloma"],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":166,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000845","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"value":"1540-336X","type":"electronic"},{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"2026-04-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}